Q1 2026. Management View "In the first quarter, we continued to advance sabirnetug through our Phase II ALTITUDE-AD trial, bu ...

Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results ...

Acumen Pharmaceuticals Inc (ABOS) showcases promising developments in Alzheimer's treatment and cost management, despite reporting a net loss for the quarter.

O’Connell’s lasting reach: A landmark film honors Daniel O’Connell’s 250th birthday, tracing his peaceful reform strategies and their influence on global civil rights movements. Occom’s untold ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs ...

The awards will be handed out a gala taking place June 28 in downtown Los Angeles.

There’s been some amount of personal growth from the first-team rookie who suffered a panic attack in the build-up to the ...

The NFL schedule release is only a day away, and fans will soon learn when each marquee matchup will take place ahead of what ...

Jerry O'Connell explained why he doesn’t go by real name Michael Jeremiah O'Connell during a Mother’s Day-themed episode of ...

Key trial timeline: Acumen plans to announce Phase II ALTITUDE-AD results in late 2026, targeting early Alzheimer's patients. EBD program plans: The company will license two EBD candidates in Q2 2026 ...

Phantom Thread, Moonlight, and Parasite are all among the very best, most perfect movies of the last 13 years.

AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Lead clinical candidate IND filing in ...